Ranked on: #13 Most Active Series B Investors of 2026 (Ranked) · #30 Most Active Series A Investors of 2026 (Ranked) · #165 Most Active Growth Investors of 2026 (Ranked) · Get your badge →
Is this your firm? Get featured or correct your listing →
At a glance
ARCH Venture Partners appears in 5 funding rounds tracked by ValueAddVC since 2026, leading 2. Its most frequent sectors in these rounds are Health & Biotech and Semiconductors & Hardware, and its most recent tracked deal was Souffle Therapeutics' $135M Series B round (Oct 13, 2026). It co-invests most often with Khosla Ventures, Bezos Expeditions and General Catalyst. ValueAddVC also tracks 6 funds managed by ARCH Venture Partners.
Strategy
Stages
SeedSeries ASeries B
Sectors
BiotechHealthcareGenomicsTherapeuticsDeep Tech
Geographies
USAChicago, Illinois, USA
Check size
$1M–$50MRecent changes
- Oct 13, 2026Oct 13, 2026Invested in Souffle Therapeutics (Series B, $135M) FinancialContent
- Oct 8, 2026Oct 8, 2026Follow-on: Invested in Oratomic (Series B, $475M) SiliconANGLE
- Sep 9, 2026Sep 9, 2026Invested in Encoded Therapeutics (Series F, $275M) Encoded Therapeutics (Business Wire via BioSpace)
- Sep 8, 2026Sep 8, 2026Invested in Moonwalk Biosciences (Series B, $70M) BioSpace
- Sep 5, 2026Sep 5, 2026Stages updated: Seed, Series A, Series B archventure.com
Earlier changes (9)
- Sep 5, 2026Sep 5, 2026Sectors updated: Biotech, Healthcare, Genomics, Therapeutics, Deep Tech archventure.com
- Sep 5, 2026Sep 5, 2026Check size updated: $1M–$50M archventure.com
- Aug 31, 2026Aug 31, 2026New fund: ARCH Venture Partners Venture Fund XIV (target $3B) SEC EDGAR Form D
- Jul 10, 2026Jul 10, 2026Invested in Oratomic (Series A, $300M) TechCrunch
- Feb 1, 2024Feb 1, 2024New fund: ARCH Venture Partners Venture Fund XIII (target $3B) SEC EDGAR Form D
- Feb 4, 2022Feb 4, 2022New fund: ARCH Venture Partners Venture Fund XII (target $2.9B) SEC EDGAR Form D
- Jan 28, 2021Jan 28, 2021New fund: ARCH Venture Partners Venture Fund XI ($1.85B) SEC EDGAR Form D
- Nov 16, 2018Nov 16, 2018New fund: ARCH Venture Partners Venture Fund X (target $675M) SEC EDGAR Form D
- May 5, 2016May 5, 2016New fund: ARCH Venture Partners Venture Fund IX (target $550M) SEC EDGAR Form D
Funds
6| Fund | Vintage | Size | Strategy | Source |
|---|---|---|---|---|
| ARCH Venture Partners Venture Fund XIV | 2026 | target $3B | Venture | As of Aug 31, 2026SEC EDGAR Form D |
| ARCH Venture Partners Venture Fund XIII | 2024 | target $3B | Venture | As of Feb 1, 2024SEC EDGAR Form D |
| ARCH Venture Partners Venture Fund XII | 2022 | target $2.9B | Venture | As of Apr 1, 2022SEC EDGAR Form D |
| ARCH Venture Partners Venture Fund XI | 2020 | $1.85B | Venture | As of Jan 28, 2021SEC EDGAR Form D |
| ARCH Venture Partners Venture Fund X | 2018 | target $675M | Venture | As of Oct 25, 2019SEC EDGAR Form D |
Show 1 earlier fund
| Fund | Vintage | Size | Strategy | Source |
|---|---|---|---|---|
| ARCH Venture Partners Venture Fund IX | 2016 | target $550M | Venture | As of Nov 18, 2016SEC EDGAR Form D |
Portfolio
13 totalRecent Investment Activity
5Track record: led 2 and participated in 3 of 5 tracked venture rounds · 5 in the last 12 months · led 1 Series B, 1 Series A
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 13, 2026 | Souffle Therapeutics | Series B | Participated | $135M | — | Fidelity InvestmentsunverifiedARCH Venture PartnersunverifiedBessemer Venture PartnersunverifiedJanus Henderson InvestorsunverifiedLeaps by BayerunverifiedPolaris PartnersunverifiedTemasekunverifiedVida VenturesunverifiedJuvia GroupTCG Crossover ManagementBB BiotechBalyasny Asset Management+5 more | FinancialContent |
| Oct 8, 2026 | Oratomic | Series B | Led | $475M | $5.5B | ARCH Venture PartnersLeadunverifiedSpark CapitalLeadunverifiedKhosla VenturesLeadunverifiedIndex VenturesLeadunverifiedGeneral CatalystLeadunverifiedBezos ExpeditionsLeadunverified | SiliconANGLE |
| Sep 9, 2026 | Encoded Therapeutics | Series F | Participated | $275M | — | Google Ventures (GV)LeadARCH Venture PartnersIllumina VenturesInvusJanus Henderson InvestorsRTW InvestmentsSoftBank Vision FundVenrockBraidwellFarallon Capital ManagementMatrix Capital ManagementNolan Capital | Encoded Therapeutics (Business Wire via BioSpace) |
| Sep 8, 2026 | Moonwalk Biosciences | Series B | Participated | $70M | — | BioSpace | |
| Jul 10, 2026 | Oratomic | Series A | Led | $300M | $7 billion | TechCrunch |
Sector / Stage Activity
By sector (portfolio)
Biotech
11 · 85%
Quantum computing
1 · 8%
By stage (tracked rounds)
Series B
3 · 60%
Series F
1 · 20%
Series A
1 · 20%
Co-Investors
12Bezos Expeditions · 2 sharedEcoR1 Capital · 2 sharedJanus Henderson Investors · 2 sharedKhosla Ventures · 2 sharedRA Capital · 2 sharedAlpha Wave Global · 1 sharedAndreessen Horowitz · 1 sharedBain Capital · 1 sharedPolaris Partners · 1 sharedRTW Investments · 1 sharedThomas Tull · 1 sharedVida Ventures · 1 shared
Similar Firms
overlapping sector, stage or regionValue Add Research
- AI & Technology · Oct 20, 2026Astromech Valuation 2026: $3.8B After a $20M Round
- Market & Trends · Oct 18, 2026Q3 2026 Semiconductor Funding Rounds: SambaNova's $1B Leads
- VC & Investing · Oct 13, 2026City Therapeutics IPO 2026: $175M Raise, CTY Ticker
- VC & Investing · Jul 31, 2026$122B OpenAI, $65B Anthropic — 2026 AI Rounds
- AI & Technology · Jul 13, 2026$300M at $1.5B — Oratomic Quantum Chip (Bezos)
- Market & Trends · Jul 10, 2026$5B+ Raised — AI Drug Discovery Startups (2026)
- AI & Technology · Jun 13, 2026Prometheus: $12B at $41B Valuation, Bezos Physical AI
Latest Pulse
- Oct 16, 2026City Therapeutics Prices Upsized $200M IPO At $18City Therapeutics priced its upsized IPO at $18 a share for about $200 million in gross proceeds, above the terms Pulse covered in early October, with Nasdaq trading under ticker CTY starting October 16.→
- Oct 13, 2026Souffle Therapeutics Raises $135M For RNA TherapiesSouffle Therapeutics closed an oversubscribed $135 million Series B led by Juvia Group on Oct. 13 to push its RNA-delivery platform's first three programs toward the clinic.→
- Oct 8, 2026Oratomic Triples To $5.5B Valuation In Three MonthsQuantum computing startup Oratomic raised a $475 million Series B at a $5.5 billion valuation, up from $1.5 billion three months ago, the same day rival Universal Quantum closed a $100 million-plus Series A.→
- Sep 8, 2026Moonwalk Biosciences Raises $70M For Obesity RNAiMoonwalk Biosciences closed an oversubscribed $70 million Series B to advance an adipose-targeted RNA interference therapy for obesity toward its first human trial, bringing total funding to roughly $127 million since its 2024 launch.→
- Jul 14, 2026Miles Wang, Ex-OpenAI Researcher, in Talks for $2B Drug-Discovery BetEx-OpenAI researcher Miles Wang is in talks to launch an AI drug-discovery startup at a roughly $2 billion valuation before the company has meaningfully operated.→
- Jul 13, 2026Quantum Computing's Venture Moment Keeps CompoundingOratomic's $300 million Series A -- Khosla's largest-ever first check -- is the clearest sign yet that VCs now treat quantum computing as its own well-capitalized category, distinct from the AI infrastructure boom.→
- Jul 10, 2026Oratomic Raises $300M to Build a 20K-Qubit Quantum ComputerOratomic, a Caltech-spinout quantum computing startup, raised a $300 million Series A to build a utility-scale quantum computer using roughly 20,000 qubits instead of the million-plus rivals are targeting.→
- Jul 10, 2026Oratomic Raises $300M for a 20,000-Qubit Quantum ComputerCaltech-founded Oratomic raised a $300 million Series A co-led by ARCH, Spark Capital and Khosla, betting its neutral-atom architecture needs only 10,000-20,000 qubits for a useful, fault-tolerant quantum computer.→
- Jun 26, 2026Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics PipelineOllin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.→
- Jun 25, 2026Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease TherapiesOllin Biosciences raised a $330 million Series B led by TCG Crossover and ARCH Venture Partners to advance its pipeline of ophthalmic therapies, one of the largest biotech rounds of the period. The deal is a reminder that even amid AI's dominance of headlines and capital, large therapeutic biotech rounds remain a major and resilient corner of venture funding.→
- Jun 10, 2026SonoThera Raises $125M for Ultrasound Gene TherapySonoThera closed an oversubscribed $125 million Series B led by Vida Ventures to push its ultrasound-delivered, nonviral genetic medicine platform toward its first clinical trial in Duchenne muscular dystrophy in 2027.→
ARCH Venture Partners FAQ
What is ARCH Venture Partners' latest fund?
ARCH Venture Partners Venture Fund XI, closed at $1.85B (As of Jan 28, 2021; SEC EDGAR Form D).
What companies has ARCH Venture Partners invested in?
ARCH Venture Partners' portfolio includes Souffle Therapeutics, Oratomic, Encoded Therapeutics, Moonwalk Biosciences, Gossamer Bio, LifeMine Therapeutics, and 7 more tracked companies.
Who does ARCH Venture Partners co-invest with most?
In the rounds Value Add tracks, ARCH Venture Partners most often invests alongside Bezos Expeditions (2 shared deals), EcoR1 Capital (2 shared deals), Janus Henderson Investors (2 shared deals), Khosla Ventures (2 shared deals), RA Capital (2 shared deals).
Sources & methodologyshow
Where these figures come from
- SEC EDGAR Form Dprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- SiliconANGLEmajor outlet1 fact
- TechCrunchmajor outlet1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.